With over 300 concurrent investigations on foot, the Australian Securities and Investments Commission has leaned heavily into its ‘why not litigate’ approach and is bringing outside help on board, including from law firms.
Otsuka changes tack in Abilify patent case after landmark Wyeth ruling
Otsuka Pharmaceuticals and Bristol Myers-Squibb are seeking to withdraw admissions in patent litigation against Generic Health over anti-psychotic drug Abilify, following a landmark ruling last year against Wyeth that clarified the issue of compensation under the usual undertaking for damages in pharmaceutical patent cases.
Ex-CEO sues live cattle exporter following ‘hostile’ and ‘demeaning’ dismissal
Live cattle exporter Wellard Ltd has been hit with an unlawful dismissal claim for more than $400,000 by its ex-CEO, who claims he was sacked for asking about the company’s troubling financial position and complaining about the chairman’s “hostile”, “demeaning” and “threatening” behaviour towards him.
Important developments in the ACCC’s cartel immunity policy and introduction of whistleblowing tool
From October 1, the Australian Competition and Consumer Commission will apply an updated cartel immunity and cooperation policy, with the changes said to reflect the ACCC’s experiences from key criminal investigations undertaken to date. The ACCC is also launching an online portal to allow whistleblowers to anonymously report alleged cartel conduct directly to the ACCC. Here, King & Wood Mallesons partner Peta Stevenson and senior associate Jacqueline Ibrahim tells you what you need to know about these significant developments.